Phenytoin Administration Guidelines
Introduction
- Phenytoin is an antiepileptic medication with a narrow therapeutic index, requiring careful dosing and monitoring to achieve therapeutic levels while minimizing adverse effects, as recommended by the American Academy of Neurology 1
Dosing and Administration
- The typical dosing regimen for phenytoin in adults is 300-400 mg/day for maintenance therapy, with an initial loading dose of 15-20 mg/kg IV at a maximum rate of 50 mg/minute when rapid therapeutic levels are needed, as recommended by the American College of Emergency Physicians 1
- For children, the loading dose is 20 mg/kg IV (maximum initial dose: 1000 mg), and for neonates, it is 10 mg/kg IV, as recommended by the American Academy of Pediatrics 2
- Fosphenytoin can be administered at a dose of 18 PE/kg IV at a maximum rate of 150 PE/min, offering a lower risk of adverse cardiac effects and faster administration, as recommended by the American Heart Association and the American Academy of Pediatrics 2, 3
- Phenytoin must be diluted in normal saline, not dextrose solutions, and requires continuous monitoring of electrocardiogram, blood pressure, and respiratory function during administration, with a reduction in infusion rate if heart rate decreases by 10 beats per minute, according to the American Academy of Pediatrics 2
Dose Adjustment and Monitoring
- When serum levels are less than 7 μg/ml, the dose should be increased by 100 mg/day, between 7-12 μg/ml by 50 mg/day, and above 12 μg/ml by 30 mg/day, allowing 7-10 days between adjustments to reach stable levels, as per the American Academy of Neurology 1
- The therapeutic range for phenytoin is typically 10-20 mcg/mL, and for a patient with a subtherapeutic level, an increase in daily maintenance dose by approximately 100 mg is recommended to achieve therapeutic levels while minimizing adverse effects, according to the American College of Emergency Physicians 1
- After dose adjustment, it is recommended to allow 7-10 days to achieve steady-state levels before rechecking phenytoin levels, to ensure accurate assessment of the new dose's effectiveness 1
Special Populations
- In patients with renal insufficiency, the American Society of Nephrology recommends using lower total serum levels due to reduced protein binding 1
- In patients with hepatic insufficiency, the American Association for the Study of Liver Diseases recommends monitoring for reduced protein binding and delayed metabolism 1
- In pregnant patients, the American College of Obstetricians and Gynecologists recommends monitoring for decreasing serum levels due to increased metabolism 1
Adverse Effects and Safety
- Common adverse effects of phenytoin include ataxia, nystagmus, tremor, and somnolence, while serious adverse effects include hypotension, bradycardia, and cardiac dysrhythmias, especially with rapid IV administration, as reported by the American Academy of Pediatrics 2, 1
- Monitoring for dose-related adverse effects, including ataxia, nystagmus, tremor, and somnolence, is essential to minimize the risk of neurotoxicity 1
- Valproate and levetiracetam are alternative treatments for refractory status epilepticus, with potentially fewer adverse effects, as supported by the American Academy of Emergency Medicine and the American Academy of Pediatrics 3
Alternative Treatments
| Medication | Dose | Efficacy |
|---|---|---|
| Valproate | 30 mg/kg IV | 88% resolution of crisis [3] |
| Levetiracetam | 30 mg/kg IV | 73% resolution of crisis [3] |
- Valproate is at least as effective as phenytoin for refractory status epilepticus, with potentially fewer adverse effects, as supported by the American Academy of Emergency Medicine and the American Academy of Pediatrics 3